+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations
O

Actively Recruiting

Researchers are observing adults diagnosed with schizophrenia in the United States who have started treatment with xanomeline and trospium chloride KarXT. The study aims to describe real-world treatment patterns, effectiveness, and adverse events related to KarXT use in routine clinical care. Participants are those who have initiated KarXT treatment within 16 weeks with plans to discontinue prior antipsychotic treatments or are on stable antipsychotic regimens planning to switch to KarXT. The study follows these participants for up to 20 weeks to record treatment titration, switches, and continuation patterns. Concomitant psychiatric medications may continue at stable doses during the study. During the study, researchers collect data on adverse events, weight changes, clinical global improvement scores, schizophrenia-related relapses, treatment discontinuation reasons, and use of antiemetic treatments for gastrointestinal symptoms. Baseline information includes demographics, family history, diagnosis duration, and previous treatments. This observational study supports understanding KarXT treatment in real-world settings up to 20 weeks after initiation.

Age: 18Years +All Genders
68 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
R

Actively Recruiting

Researchers are comparing two approaches for treating patients who have a deep brain bleed called intracerebral hemorrhage. The study evaluates whether early minimally invasive surgery to remove the blood clot is better than standard medical care, which includes intensive monitoring, blood pressure control, and other treatments to prevent further bleeding or stroke. This trial aims to find improved recovery methods for this type of stroke, which is challenging to treat, especially when the bleeding is deep within the brain. Participants are randomly assigned to one of two groups surgical management plus medical care or medical care alone. The surgical group undergoes minimally invasive surgery performed by trained neurosurgeons within 24 hours of symptom onset to remove the clot. The medical management group receives care based on current clinical guidelines, including intensive care unit admission, blood pressure control, and other supportive treatments. Both groups follow detailed clinical standardization guidelines throughout their care. Throughout the study, participants are closely monitored with various assessments, including imaging to measure hematoma volume, neurological evaluations, and tracking of survival and adverse events. The main outcome measured is the patients functional status 180 days after randomization using the modified Rankin Scale. Additional outcomes include mortality rates during hospitalization and at 30 days, ICU length of stay, mechanical ventilation duration, and incidence of complications. The study aims to provide clear evidence on which treatment approach offers better recovery for patients with deep brain bleeding.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
24 locations